Veloxity Labs Selected as Bioanalytical Partner for Silo Pharma’s IND-Enabling Study

We’re proud to announce that Silo Pharma, Inc. (Nasdaq: SILO) has selected Veloxity Labs as its bioanalytical vendor for preclinical IND-enabling work on SPC-15—a novel intranasal therapy targeting post-traumatic stress disorder (PTSD).

As part of this collaboration, we're supporting GLP-compliant toxicology and toxicokinetics sample analysis, providing high-integrity data to help advance SPC-15 toward a first-in-human clinical trial. Silo expects to submit an IND to the FDA in 2025.

We’re honored to be part of this promising program and look forward to contributing to its success.

👉 Read the full announcement

📩 Working on a preclinical or clinical program? Contact us to learn how Veloxity Labs can support your bioanalytical needs.